ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2021
Risk of Late-Onset Breast Cancer in Genetically Predisposed Women.
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 38 citations in OpenAlex.
- ASO Author Reflections: Risk Management Strategies for Older Women With Germline Pathogenic Variants in BRCA1/2 and PALB2.Annals of surgical oncology · 2026Article
- Uptake of Risk Reducing Mastectomy in Older BRCA1/2 and PALB2 Carriers Undergoing Genetic Testing after 60 Years of Age.Annals of surgical oncology · 2026Article
- Clinical outcome and proportion of hereditary cancer genes gPV in TNBC: the HEaRTBeat study.NPJ breast cancer · 2025Article
- Genomic landscape of breast cancer in elderly patients.NPJ breast cancer · 2025Article
- Pathogenic Variants in Cancer Susceptibility Genes Predispose to Ductal Carcinoma In Situ of the Breast.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
- Mainstream Germline Genetic Testing with Expanded Eligibility for Early Breast Cancer Patients in a Large Integrated Health System.Annals of surgical oncology · 2025Article
- Translational breast cancer research : a journal focusing on translational research in breast cancer · 2025Review
- Breast Cancer Susceptibility Gene Sequence Variations and Development of Contralateral Breast Cancer.JAMA network open · 2024Article
- Multi-Gene Panel Testing for Hereditary Cancer Predisposition Among Patients Sixty-Five Years and Above Diagnosed With Breast Cancer.World journal of oncology · 2024Article
- Germline Genetic Testing for Hereditary Breast and Ovarian Cancer: Current Concepts in Risk Evaluation.Cold Spring Harbor perspectives in medicine · 2024Review
- Universal genetic counseling in breast cancer patients significantly improves overall testing rates and improves completion rates in subpopulations.Breast cancer research and treatment · 2024Article
- Breast cancer diagnosed after age 70 years in Israeli BRCA1/BRCA2 pathogenic sequence variant carriers: a single institution experience.Breast cancer research and treatment · 2024Article
- Hereditary cancer testing in a diverse sample across three breast imaging centers.Breast cancer research and treatment · 2024Article
- Review
- What is the appropriate genetic testing criteria for breast cancer in the Chinese population?-Analysis of genetic and clinical features from a single cancer center database.Cancer medicine · 2023Article
- The association between age at breast cancer diagnosis and prevalence of pathogenic variants.Breast cancer research and treatment · 2023Article
- BRCA1 and BRCA2 germline mutation analysis from a cohort of 1267 patients at high risk for breast cancer in Brazil.Breast cancer research and treatment · 2023Article
- Contralateral Breast Cancer Risk Among Carriers of Germline Pathogenic Variants inJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Article
- Accurate genome-wide genotyping from archival tissue to explore the contribution of common genetic variants to pre-cancer outcomes.Journal of translational medicine · 2022Article
- Controversies and Open Questions in Management of Cancer-Free Carriers of Germline Pathogenic Variants inCancers · 2022Review
Corrections and comments
- Commented on by
Authors and funding
51 authors at 16 institutions in 2 countries.
Funding
Abstract
purposeThe prevalence of germline pathogenic variants (PVs) in established breast cancer predisposition genes in women in the general population over age 65 years is not well-defined. However, testing guidelines suggest that women diagnosed with breast cancer over age 65 years might have < 2.5% likelihood of a PV in a high-penetrance gene. This study aimed to establish the frequency of PVs and remaining risks of breast cancer for each gene in women over age 65 years.
methodsA total of 26,707 women over age 65 years from population-based studies (51.5% with breast cancer and 48.5% unaffected) were tested for PVs in germline predisposition gene. Frequencies of PVs and associations between PVs in each gene and breast cancer were assessed, and remaining lifetime breast cancer risks were estimated for non-Hispanic White women with PVs.
resultsThe frequency of PVs in predisposition genes was 3.18% for women with breast cancer and 1.48% for unaffected women over age 65 years. PVs in
conclusionThis study suggests that all women diagnosed with triple-negative breast cancer or ER-negative breast cancer should receive genetic testing and that women over age 65 years with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.